Senate, House Draft Reauthorization Bill to Increase Drug, Medical Device User Fees
By Zachary Brennan -
Published 14 April 2017
With an aim to avoid thousands of US Food and Drug Administration (FDA) employee layoffs, House and Senate committees on Friday released a draft bill to reauthorize the user fee programs for pharmaceuticals, generic drugs, medical devices and biosimilars from 2018 to 2022.
Categories: News, US, FDA, Active pharmaceutical ingredients, Biologics and biotechnology, Combination products, Drugs, Due Diligence, Government affairs, Medical Devices, Regulatory intelligence, Regulatory strategy
Tags: user fee reauthorization, FDA user fees, drug review fees